Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer centerJeffrey Xia, Sukeshi Patel Arora, Jonathan Gelfond|Journal of Gastrointestinal Oncology|2021Cited by 5
Second-line tyrosine kinase inhibitors (TKIs) versus immunotherapy (IO) for advanced hepatocellular carcinoma (HCC): Real-world efficacy and safety analysis in patients with varying liver dysfunction.Jeffrey Xia, Sukeshi Patel Arora, Jonathan Gelfond|Journal of Clinical Oncology|2021Cited by 0